Baidu
map

Clin Microbiol Infect:带状疱疹感染史与更高的卒中/TIA风险有关

2016-07-12 zhaoshuang 译 MedSci原创

根据韩国一项研究的数据显示,带状疱疹病毒感染的患者出现卒中或短暂性脑缺血发作(TIA)的风险增加了。峨山医学中心的传染病部门的流行病学家和研究员Sung-Han U. Kim博士进行了一项基于人群的队列研究,调查带状疱疹(HZ)和卒中发病率之间的关联。该研究纳入了766179例患者,随访11年,首诊HZ感染发病率为9.4/1000人年(95% CI, 9.33-9.47),首诊卒中/TIA的发病率

根据韩国一项研究的数据显示,带状疱疹病毒感染的患者出现卒中或短暂性脑缺血发作(TIA)的风险增加了。

峨山医学中心的传染病部门的流行病学家和研究员Sung-Han U. Kim博士进行了一项基于人群的队列研究,调查带状疱疹(HZ)和卒中发病率之间的关联。

该研究纳入了766179例患者,随访11年,首诊HZ感染发病率为9.4/1000人年(95% CI, 9.33-9.47),首诊卒中/TIA的发病率为9.77/1000人年(95% CI, 9.7-9.84)。这两种结果的发病率随着年龄的增加而增加(P < .001),HZ在女性中更为普遍(P < .001)。

研究者发现,既往HZ与没有的相比,卒中/TIA风险更大(IRR=1.9; 95% CI, 1.85-1.95);不过增加的风险和年龄也有关,18-30岁人群的风险最高(aHR=1.52; 95% CI, 1.26-1.83)。此外,研究人员指出,不管HZ感染后多少年,卒中/TIA的风险持续处于增加状态。

“我们发现,感染HZ后很长一段时间的卒中风险都增加,即使我们调整了其他已知的卒中危险因素,”研究者说。“这表明,感染这种病毒是脑卒中或TIA的独立风险因子。”

原始出处:

Kwon SU, et al. Risk of stroke and transient ischaemic attack after herpes zoster.Clin Microbiol Infect. 2016;doi:10.1016/j.cmi.2016.03.003.

Herpes zoster infection increases risk for stroke, TIA.
Healio.July 11, 2016


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2084156, encodeId=d327208415627, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Jan 25 10:40:00 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767025, encodeId=42541e67025a7, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Jan 29 15:40:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857383, encodeId=4efc185e3838a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Nov 08 02:40:00 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145578, encodeId=8b291455e861, content=好文,值得推荐。, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 20:38:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141767, encodeId=2fda141e675f, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:38:46 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917303, encodeId=69fc191e303bd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 12 12:40:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580367, encodeId=6441158036e84, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Jul 14 03:40:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
    2017-01-25 xjy02
  2. [GetPortalCommentsPageByObjectIdResponse(id=2084156, encodeId=d327208415627, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Jan 25 10:40:00 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767025, encodeId=42541e67025a7, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Jan 29 15:40:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857383, encodeId=4efc185e3838a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Nov 08 02:40:00 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145578, encodeId=8b291455e861, content=好文,值得推荐。, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 20:38:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141767, encodeId=2fda141e675f, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:38:46 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917303, encodeId=69fc191e303bd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 12 12:40:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580367, encodeId=6441158036e84, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Jul 14 03:40:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2084156, encodeId=d327208415627, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Jan 25 10:40:00 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767025, encodeId=42541e67025a7, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Jan 29 15:40:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857383, encodeId=4efc185e3838a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Nov 08 02:40:00 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145578, encodeId=8b291455e861, content=好文,值得推荐。, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 20:38:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141767, encodeId=2fda141e675f, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:38:46 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917303, encodeId=69fc191e303bd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 12 12:40:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580367, encodeId=6441158036e84, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Jul 14 03:40:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2084156, encodeId=d327208415627, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Jan 25 10:40:00 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767025, encodeId=42541e67025a7, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Jan 29 15:40:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857383, encodeId=4efc185e3838a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Nov 08 02:40:00 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145578, encodeId=8b291455e861, content=好文,值得推荐。, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 20:38:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141767, encodeId=2fda141e675f, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:38:46 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917303, encodeId=69fc191e303bd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 12 12:40:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580367, encodeId=6441158036e84, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Jul 14 03:40:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
    2016-10-11 ylzr123

    好文,值得推荐。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2084156, encodeId=d327208415627, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Jan 25 10:40:00 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767025, encodeId=42541e67025a7, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Jan 29 15:40:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857383, encodeId=4efc185e3838a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Nov 08 02:40:00 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145578, encodeId=8b291455e861, content=好文,值得推荐。, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 20:38:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141767, encodeId=2fda141e675f, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:38:46 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917303, encodeId=69fc191e303bd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 12 12:40:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580367, encodeId=6441158036e84, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Jul 14 03:40:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
    2016-10-08 1e10c84am36(暂无匿称)

    文章很棒,继续学习

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=2084156, encodeId=d327208415627, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Jan 25 10:40:00 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767025, encodeId=42541e67025a7, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Jan 29 15:40:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857383, encodeId=4efc185e3838a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Nov 08 02:40:00 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145578, encodeId=8b291455e861, content=好文,值得推荐。, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 20:38:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141767, encodeId=2fda141e675f, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:38:46 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917303, encodeId=69fc191e303bd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 12 12:40:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580367, encodeId=6441158036e84, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Jul 14 03:40:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]
    2017-03-12 sunylz
  7. [GetPortalCommentsPageByObjectIdResponse(id=2084156, encodeId=d327208415627, content=<a href='/topic/show?id=61f411e013b' target=_blank style='color:#2F92EE;'>#Micro#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11701, encryptionId=61f411e013b, topicName=Micro)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d59291, createdName=xjy02, createdTime=Wed Jan 25 10:40:00 CST 2017, time=2017-01-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1767025, encodeId=42541e67025a7, content=<a href='/topic/show?id=64f5343e2f' target=_blank style='color:#2F92EE;'>#Biol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3437, encryptionId=64f5343e2f, topicName=Biol)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=446937890434, createdName=12498ebem31暂无昵称, createdTime=Sun Jan 29 15:40:00 CST 2017, time=2017-01-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1857383, encodeId=4efc185e3838a, content=<a href='/topic/show?id=3f48525849' target=_blank style='color:#2F92EE;'>#CRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=86, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5258, encryptionId=3f48525849, topicName=CRO)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Tue Nov 08 02:40:00 CST 2016, time=2016-11-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=145578, encodeId=8b291455e861, content=好文,值得推荐。, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/NUyjXTCJjo7s7ZCKOmmbBTD6nE7gcd5OZpvyGEzkxBP3S275k5ZJVrsPkotZhBglRHM9rKvcj1OgkssqhcnoPw8zIaMZTF8c/0, createdBy=4c441942088, createdName=ylzr123, createdTime=Tue Oct 11 20:38:18 CST 2016, time=2016-10-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=141767, encodeId=2fda141e675f, content=文章很棒,继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Sat Oct 08 08:38:46 CST 2016, time=2016-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917303, encodeId=69fc191e303bd, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Sun Mar 12 12:40:00 CST 2017, time=2017-03-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1580367, encodeId=6441158036e84, content=<a href='/topic/show?id=c026e05485f' target=_blank style='color:#2F92EE;'>#疱疹#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70548, encryptionId=c026e05485f, topicName=疱疹)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2dcf16628144, createdName=ms2694732865965676, createdTime=Thu Jul 14 03:40:00 CST 2016, time=2016-07-14, status=1, ipAttribution=)]

相关资讯

NEJM:GSK推出预防带状疱疹新疫苗

带状疱疹是由位于背部以及头盖神经节处的潜在的水痘-带状疱疹病毒(VZV)再活化导致的,通常在首次感染数十年后发生。超过90%的成年人被VZV感染,有患上带状疱疹的风险。尽管带状疱疹在超过50岁或者年龄更大的人群中频发(由于免疫衰老),但带状疱疹也可以在细胞介导免疫功能因疾病或药物治疗而下降时,在各个年龄都可能发生。默克公司的抗带状病毒疫苗Zostavax包含了Oka VZV病毒株,可以用于50岁及

J Allergy Clin Immun:特殊体质患者不宜接种带状疱疹疫苗

根据最新发表在Journal of Allergy and Clinical Immunology杂志上的一篇文章,哮喘是成年带状疱疹患者的一类潜在并发症。医生们在给患者注射带状疱疹疫苗时要谨慎考虑。 来自韩国首尔的Catholic大学医学院的Hyo Jin Kwon医生等人汇总分析了带状疱疹患者的相关病历资料。总共得到371名患者病例以及742份对照病例。 根据病例资料分析得出:在带状疱疹患

默克与赛诺菲正式“离婚”,不再联手在欧洲销售疫苗

默克公司(Merck & Co.)和赛诺菲巴斯德公司(Sanofi Pasteur)正在结束联姻于1994年的在欧洲销售这两家公司疫苗的合资公司。 该合资企业当前在19个国家销售25种疫苗,包括默克公司的带状疱疹疫苗Zostavax和赛诺菲巴斯德公司的流感疫苗Intanza。 在一项联合声明中,它们说,这家五五开的合资企业已在商业和公共卫生上取得成功,但是“独立地管理我们的

Mayo Clin Proc:美国老年人带状疱疹发生后,心肌梗死和卒中发生风险增加

目的:旨在评估美国社区老年人群中带状疱疹后,卒中和心肌梗死(MI)发生的风险。病人和方法:研究者进行了一项社区队列研究(1986年1月1日至2011年10月1日)比较明尼苏达奥姆斯特德县50岁及以上的有无带状疱疹的居民,和按照性别和年龄相匹配的无带状疱疹史的受试者卒中和MI发生的风险。指标性带状疱疹后3、6、12、36个月后加为长期风险的危险比(长达28.6年)来表示心肌梗死和中风的OR值。结果:

带状疱疹后神经痛的危险因素和预防

在出疹前就出现疼痛,可能是带状疱疹后遗神经痛的危险因素(Pooled effect estimate 2.29, 95%CI=1.42~3.69)。  2. 尽管不同文献对“剧烈疼痛”的定义不同,但带状疱疹时的严重的疼痛与之后罹患疱疹后遗神经痛的风险有非常明确的相关性(RR=2.23,95%CI=1.71-2.92)。  3. 影响日常功能的疼痛。对两项研究的汇总分析提示影响日常功能的带状疱疹

PLoS Med:带状疱疹增加中风和心脏病的发作风险!

发表在PLOS Medicine的新进研究表明,带状疱疹可增加民众患急性缺血性中风和心肌梗死等心血管疾病或心脏病的风险。 带状疱疹病毒是一种常见的病毒,每年约100万美国人感染,极有可能对民众带来严重后果。 带状疱疹病毒可导致民众患水痘和带状疱疹。民众患水痘之后,病毒在在机体内长期存在,长期保持休眠状态。如果多年以后病毒活跃起来,可导致机体患带状疱疹,皮疹可引起剧烈的疼痛并长期持续,成为疱疹后神经

Baidu
map
Baidu
map
Baidu
map